A Phase 3 interventional study of Secukinumab and Placebo in Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 23rd largest by enrollment, is one of 3 that started in 2014, is one of 24 in phase 3, and was the 29th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 29th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2014, is one of 30 in phase 3, and was the 38th registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endothelial dysfunction and arterial stiffness after 12 weeks and for up to 52 weeks in subjects with chronic plaque-type psoriasis. Furthermore soluble biomarkers were assessed to evaluate the influence of secukinumab on cardiovascular risk. Magnetic resonance imaging (MRI) was performed in a sub-population to assess the treatment effect on arterial vessel wall morphometry in atherosclerosis prone vascular beds.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
Drug: Secukinumab
150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
Drug: Secukinumab
Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
Other: Placebo
Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
Other: Placebo
300 mg secukinumab
Also known as: AIN457
Placebo followed by 300 mg secukinumab
Placebo followed by 150 mg secukinumab
150 mg secukinumab
Also known as: AIN457
Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment
Flow Mediated Dilation (FMD) is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 millimeter of mercury (mmHg) for 4.5 minutes and for 4.5 minutes following deflation.
Time frame: Week 12
Change From Baseline in Flow Mediated Dilation (FMD) at Week 4, 12, 24 and 52
FMD is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 mmHg for 4.5 minutes and for 4.5 minutes following deflation. A positive change in FMD constitutes an improvement in endothelial function.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Aortic Augmentation Index at Heart Rate of 75 (AIx-75) at Week 4, 12, 24 and 52
Pulse wave analysis was performed on the central aortic pressure waveform as derived by SphygmoCor XCEL from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. The waveform derivation employs a validated generalized transfer function to convert a brachial waveform to a central waveform and has been shown to produce measurement results corresponding to measurements using intra-arterial pressure catheters. The augmentation index is derived from the waveform by determining the percentage of the central pulse pressure during systole due to wave reflection. AIx was heart-rate corrected to calculate the AIx at a heart rate of 75 bpm, i.e. AIx-75.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Pulse Wave Velocity (PWV) at Week 4, 12, 24 and 52
Regional arterial pulse wave velocity (PWV) was directly related to arterial stiffness and was defined as the time it takes for the blood pressure wave to travel from a proximal site to a distal site (relative to the heart) divided by the distance (PWV = ∆distance/∆time \[m/s\]). The foot of the arterial pulse wave was being recorded by using the SphygmoCor XCEL device. XCEL simultaneously measures the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand-held applanation tonometry). The foot-to-foot time between the two pressure waveforms was the time interval used in the PWV calculation.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 12
Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.
Time frame: Baseline, Week 12
Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 52
Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.
Time frame: Baseline, Week 52
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 4, 12, 24 and 52
High sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in S-100 Protein B (Total) at Week 4, 12, 24 and 52
S100 calcium-binding protein B (S100B-protein), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Chemokine (C-c Motif) Ligand 5 (CCL5), Monocyte Chemoattractant Protein 1 (MCP-1) and Macrophage Inflammatory Proteins (MIP) 1 Alpha and 1 Beta at Week 4, 12, 24 and 52
Chemokine (c-c motif) ligand 5 (CCL5), Monocyte chemoattractant protein 1 (MCP-1) and Macrophage inflammatory proteins (MIP) 1 alpha (1A) and 1 beta (1B), soluble biomarkers of systemic inflammation were determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4, 12, 24 and 52
Fasting plasma glucose (FPG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Fasting Insulin at Week 4, 12, 24 and 52
Fasting Insulin, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Homeostatic Model Assessment (HOMA) Beta-cell Function at Week 4, 12, 24 and 52
Homeostatic Model Assessment (HOMA) beta-cell function, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Homeostatic Model Assessment (HOMA) Insulin Resistance at Week 4, 12, 24 and 52
HOMA insulin resistance, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Hemoglobin A1c (Glycated Hemoglobin) at Week 4, 12, 24 and 52
Hemoglobin A1c (glycated hemoglobin), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Sex Hormone-binding Globulin (SHBG) at Week 4, 12, 24 and 52
Sex hormone-binding globulin (SHBG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Triglycerides, Total Cholesterol, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB) at Week 4, 12, 24 and 52
Triglycerides, Total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB), soluble biomarkers of impaired lipid metabolism were determined in fasting blood samples to evaluate the effect of secukinumab on impaired lipid metabolism.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Adiponectin at Week 4, 12, 24 and 52
Adiponectin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
Time frame: Baseline, Week 4, 12, 24 and 52
Change From Baseline in Leptin at Week 4, 12, 24 and 52
Leptin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
Time frame: Baseline, Week 4, 12, 24 and 52
The study was conducted at 23 centers in Germany.
| Milestone | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Started | 48 | 54 | 26 | 23 |
| Completed | 47 | 49 | 24 | 20 |
| Not completed | 1 | 5 | 2 | 3 |
| Withdrew: Progressive disease | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 2 | 2 |
| Withdrew: Patient/guardian decision | 1 | 2 | 0 | 1 |
Flow Mediated Dilation (FMD) is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 millimeter of mercury (mmHg) for 4.5 minutes and for 4.5 minutes following deflation.
| Percentage maximal increase in diameter | Secukinumab 300 mg | Placebo (Pooled) |
|---|---|---|
| Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment | 5.23 ± 5.30 | 3.65 ± 4.07 |
FMD is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 mmHg for 4.5 minutes and for 4.5 minutes following deflation. A positive change in FMD constitutes an improvement in endothelial function.
| Percentage change in FMD | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | -0.7 (-1.9 to 0.5) | -0.9 (-2.4 to 0.7) | 0.7 (-1.0 to 2.5) | 1.4 (-0.8 to 3.6) |
| Week 12 | 0.5 (-1.1 to 2.1) | 0.1 (-1.2 to 1.5) | -0.1 (-2.7 to 2.4) | 0.1 (-2.1 to 2.3) |
| Week 24 | -0.8 (-1.9 to 0.3) | 1.0 (-0.4 to 2.4) | -0.0 (-2.6 to 2.6) | 0.9 (-1.0 to 2.9) |
| Week 52 | 2.1 (0.8 to 3.3) | 2.1 (0.7 to 3.4) | 2.2 (-0.5 to 4.9) | 1.2 (-1.0 to 3.5) |
Pulse wave analysis was performed on the central aortic pressure waveform as derived by SphygmoCor XCEL from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. The waveform derivation employs a validated generalized transfer function to convert a brachial waveform to a central waveform and has been shown to produce measurement results corresponding to measurements using intra-arterial pressure catheters. The augmentation index is derived from the waveform by determining the percentage of the central pulse pressure during systole due to wave reflection. AIx was heart-rate corrected to calculate the AIx at a heart rate of 75 bpm, i.e. AIx-75.
| Percentage change in Alx-75 | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | 0.0 (-2.8 to 2.9) | 0.3 (-2.0 to 2.7) | 1.1 (-1.7 to 3.8) | -0.1 (-3.0 to 2.9) |
| Week 12 | -0.5 (-3.0 to 2.1) | 1.0 (-1.7 to 3.8) | -1.1 (-5.4 to 3.3) | -0.1 (-3.4 to 3.2) |
| Week 24 | 3.0 (0.3 to 5.6) | 1.8 (-0.6 to 4.3) | 1.3 (-2.7 to 5.3) | 0.7 (-2.7 to 4.1) |
| Week 52 | 1.3 (-1.5 to 4.2) | -0.1 (-2.8 to 2.7) | -1.4 (-5.8 to 2.9) | -0.9 (-4.2 to 2.5) |
Regional arterial pulse wave velocity (PWV) was directly related to arterial stiffness and was defined as the time it takes for the blood pressure wave to travel from a proximal site to a distal site (relative to the heart) divided by the distance (PWV = ∆distance/∆time \[m/s\]). The foot of the arterial pulse wave was being recorded by using the SphygmoCor XCEL device. XCEL simultaneously measures the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand-held applanation tonometry). The foot-to-foot time between the two pressure waveforms was the time interval used in the PWV calculation.
| meters per second (m/s) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 (n = 192, 262, 133, 104) | 0.0 (-0.2 to 0.2) | -0.2 (-0.3 to 0.0) | 0 (-0.1 to 0.2) | -0.2 (-0.5 to 0.2) |
| Week 12 (n = 214, 255, 116, 133) | 0.4 (0.2 to 0.6) | 0.1 (-0.1 to 0.2) | 0.1 (-0.2 to 0.4) | 0.4 (0.1 to 0.7) |
| Week 24 (n = 205, 255, 100, 100) | 0.2 (-0.1 to 0.5) | 0.0 (-0.2 to 0.1) | 0.2 (0.1 to 0.4) | -0.1 (-0.5 to 0.2) |
| Week 52 (n = 191, 228, 115, 101) | -0.1 (-0.3 to 0.0) | 0.2 (-0.1 to 0.5) | 0.1 (-0.2 to 0.4) | -0.2 (-0.6 to 0.2) |
Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.
| millimeter square (mm^2) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Ascending thoracic aorta | 15.35 (-8.23 to 38.92) | 5.91 (-13.09 to 24.91) | 9.92 (-58.24 to 78.08) | 6.45 (-9.26 to 22.15) |
| Descending thoracic aorta | 2.69 (-14.18 to 19.56) | -2.94 (-13.44 to 7.57) | -4.04 (-29.61 to 21.53) | 3.16 (-13.73 to 20.05) |
| Carotid bifurcation left | 0.52 (-2.72 to 3.77) | -1.08 (-3.85 to 1.69) | 3.63 (-7.82 to 15.08) | 1.12 (-2.04 to 4.28) |
| Carotid bifurcation right | -0.77 (-3.60 to 2.06) | 1.75 (-0.71 to 4.21) | -1.26 (-7.64 to 5.12) | -1.07 (-4.24 to 2.10) |
| Common carotid left | 0.17 (-1.64 to 1.99) | 1.12 (-1.80 to 4.03) | 0.69 (-5.21 to 6.59) | 0.12 (-1.91 to 2.15) |
| Common carotid right | -0.12 (-2.17 to 1.92) | 0.30 (-2.76 to 3.36) | -0.38 (-6.56 to 5.80) | -0.14 (-1.60 to 1.32) |
| Internal carotid left | 3.79 (-0.19 to 7.78) | 2.09 (-0.57 to 4.75) | 2.59 (-0.58 to 5.77) | -1.74 (-4.55 to 1.08) |
| Internal carotid right | -0.69 (-1.90 to 0.51) | 0.17 (-1.96 to 2.30) | 0.68 (-3.97 to 5.33) | -1.37 (-4.37 to 1.62) |
| Descending abdominal aorta | 8.71 (-6.33 to 23.76) | -3.79 (-21.90 to 14.32) | 4.56 (-52.64 to 61.77) | -0.58 (-15.51 to 14.35) |
Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.
| mm^2 | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Ascending thoracic aorta | 14.42 (-14.93 to 43.76) | 3.19 (-17.17 to 23.55) | -15.11 (-28.15 to -2.06) | 9.54 (-14.71 to 33.79) |
| Descending thoracic aorta | 3.97 (-13.42 to 21.37) | 2.55 (-12.23 to 17.33) | -10.14 (-34.05 to 13.77) | 1.14 (-26.76 to 29.05) |
| Carotid bifurcation left | 2.45 (-1.55 to 6.45) | 0.64 (-3.59 to 4.88) | 0.58 (-9.03 to 10.20) | 2.60 (-2.16 to 7.36) |
| Carotid bifurcation right | -1.64 (-6.02 to 2.74) | -0.05 (-3.62 to 3.51) | -3.23 (-9.86 to 3.40) | 1.25 (-3.92 to 6.41) |
| Common carotid left | 1.42 (-0.36 to 3.19) | 1.21 (-1.51 to 3.93) | 0.65 (-2.82 to 4.13) | 1.00 (-0.83 to 2.82) |
| Common carotid right | 0.02 (-2.54 to 2.58) | 0.23 (-2.29 to 2.75) | -0.80 (-6.25 to 4.64) | -1.38 (-3.33 to 0.57) |
| Internal carotid left | 5.43 (1.21 to 9.65) | 3.59 (0.59 to 6.60) | 1.06 (-2.66 to 4.78) | 0.33 (-5.07 to 5.73) |
| Internal carotid right | -1.07 (-2.12 to -0.03) | 0.71 (-1.78 to 3.21) | -0.20 (-3.89 to 3.49) | 0.13 (-2.22 to 2.48) |
| Descending abdominal aorta | 10.56 (-8.37 to 29.48) | -4.36 (-17.90 to 9.19) | 12.46 (-46.12 to 71.05) | 11.82 (-15.26 to 38.90) |
High sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
| Milligrams per deciliter (mg/dL) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | 0.0 (-0.2 to 0.2) | -0.2 (-0.4 to -0.1) | -0.0 (-0.2 to 0.2) | 0.1 (-0.1 to 0.3) |
| Week 12 | -0.0 (-0.3 to 0.3) | -0.2 (-0.3 to 0.0) | -0.3 (-0.8 to 0.1) | 0.1 (-0.4 to 0.6) |
| Week 24 | -0.0 (-0.3 to 0.2) | -0.0 (-0.3 to 0.2) | 0.1 (-0.2 to 0.4) | -0.4 (-0.9 to 0.1) |
| Week 52 | -0.1 (-0.3 to 0.1) | -0.2 (-0.4 to -0.0) | -0.3 (-0.8 to 0.2) | -0.5 (-1.1 to 0.0) |
S100 calcium-binding protein B (S100B-protein), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
| Microgram per Liter (ug/L) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | -0.0 (-0.0 to -0.0) | -0.0 (-0.0 to 0.0) | 0.0 (-0.0 to 0.0) | 0.0 (-0.0 to 0.0) |
| Week 12 | -0.0 (-0.0 to 0.0) | -0.0 (-0.0 to 0.0) | 0.0 (-0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Week 24 | -0.0 (-0.0 to 0.0) | 0.0 (-0.0 to 0.0) | 0.0 (-0.0 to 0.0) | 0.0 (-0.0 to 0.0) |
| Week 52 | -0.0 (-0.0 to 0.0) | -0.0 (-0.0 to -0.0) | 0.0 (-0.0 to 0.0) | -0.0 (-0.0 to 0.0) |
Chemokine (c-c motif) ligand 5 (CCL5), Monocyte chemoattractant protein 1 (MCP-1) and Macrophage inflammatory proteins (MIP) 1 alpha (1A) and 1 beta (1B), soluble biomarkers of systemic inflammation were determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
| picograms per milliliter (pg/mL) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| CCL5 Week 4 | -1000 (-3106 to 1094) | 1649 (-597 to 3895) | 27.0 (-3943 to 3997) | -2000 (-5056 to 281.3) |
| CCL5 Week 12 | 2116 (-2368 to 6599) | 5185 (840.3 to 9530) | 4393 (-1598 to 10383) | 3002 (-1806 to 7809) |
| CCL5 Week 24 | 7772 (3766 to 11777) | 10000 (6437 to 14394) | 11000 (2117 to 20176) | 9168 (2124 to 16212) |
| CCL5 Week 52 | 1515 (-2478 to 5507) | 3577 (-737 to 7891) | -597 (-3340 to 2145) | 2308 (-2558 to 7175) |
| MCP-1 Week 4 | -7.0 (-21.8 to 7.7) | 1.4 (-17.4 to 20.2) | -25 (-57.2 to 8.0) | 17.5 (-43.1 to 78.0) |
| MCP-1 Week 12 | 18.4 (-1.9 to 38.7) | 28.6 (-8.4 to 65.7) | 11.3 (-40.9 to 63.5) | 21.5 (-18.3 to 61.2) |
| MCP-1 Week 24 | 39.8 (-0.6 to 80.3) | 241 (-203 to 685.7) | -20 (-53.9 to 14.2) | 33.4 (8.3 to 58.5) |
| MCP-1 Week 52 | 22.1 (-18.1 to 62.4) | 25.4 (-21.7 to 72.6) | -11 (-60.6 to 38.6) | 109 (-13.3 to 230.9) |
| MIP-1A Week 4 | -0.1 (-2.1 to 1.9) | 0.1 (-1.6 to 1.8) | 0.5 (-2.5 to 3.5) | -0.6 (-2.3 to 1.2) |
| MIP-1A Week 12 | 0.2 (-2.8 to 3.3) | 2.2 (-1.0 to 5.3) | -3.6 (-7.0 to -0.3) | 0.9 (-3.0 to 4.8) |
| MIP-1A Week 24 | -0.2 (-2.9 to 2.4) | -0.5 (-3.6 to 2.6) | -4.7 (-8.4 to -1.0) | 1.7 (-1.3 to 4.7) |
| MIP-1A Week 52 | 4.3 (-0.1 to 8.7) | 0.8 (-3.0 to 4.5) | 1.7 (-6.0 to 9.5) | 20.1 (4.7 to 35.6) |
| MIP-1B Week 4 | -24 (-50.8 to 3.0) | -2.6 (-24.8 to 19.5) | -16 (-57.5 to 25.8) | -20 (-54.4 to 15.3) |
| MIP-1B Week 12 | -49 (-80.9 to -16.6) | -34 (-69.0 to 1.4) | -65 (-106 to -24.7) | -68 (-116 to -20.5) |
| MIP-1B Week 24 | -52 (-130 to 26.7) | -97 (-133 to -61.3) | -161 (-207 to -114) | 79.4 (-261 to 420.3) |
| MIP-1B Week 52 | -41 (-73.6 to -8.6) | -59 (-89.0 to -29.7) | -73 (-122 to -24.2) | -31 (-109 to 46.8) |
Fasting plasma glucose (FPG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
| mg/dL | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | 1.5 (-1.0 to 4.0) | -1.6 (-4.6 to 1.3) | 0.9 (-4.4 to 6.1) | 0.2 (-5.2 to 5.6) |
| Week 12 | 3.5 (-0.0 to 7.0) | 1.1 (-4.0 to 6.2) | 5.3 (-2.2 to 12.8) | -1.5 (-7.1 to 4.0) |
| Week 24 | 2.5 (0.0 to 5.0) | 1.4 (-6.3 to 9.1) | 12.1 (-10.8 to 35.0) | -1.4 (-7.7 to 5.0) |
| Week 52 | -0.8 (-3.5 to 2.0) | 0.7 (-3.0 to 4.4) | 8.7 (-7.5 to 25.0) | 0.9 (-6.7 to 8.6) |
Fasting Insulin, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
| micro units per millilitre (uU/mL) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | 0.4 (-2.0 to 2.7) | 0.4 (-2.3 to 3.0) | -4.7 (-17.4 to 8.1) | -0.5 (-4.8 to 3.7) |
| Week 12 | -1.4 (-5.1 to 2.4) | 1.1 (-2.7 to 4.8) | -2.2 (-9.2 to 4.7) | -0.1 (-4.9 to 4.7) |
| Week 24 | -1.0 (-4.1 to 2.0) | 0.5 (-3.7 to 4.8) | -5.3 (-18.5 to 8.0) | -2.0 (-6.1 to 2.0) |
| Week 52 | -0.4 (-4.3 to 3.6) | 1.5 (-1.3 to 4.2) | -1.2 (-7.5 to 5.1) | 3.0 (-5.2 to 11.3) |
Homeostatic Model Assessment (HOMA) beta-cell function, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
| Percentage | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | -18 (-64.7 to 28.2) | -0.2 (-25.7 to 25.3) | -28 (-88.4 to 33.0) | -8.9 (-38.5 to 20.7) |
| Week 12 | -16 (-74.4 to 41.5) | 3.9 (-32.0 to 39.8) | -29 (-100 to 41.6) | 16.6 (-20.6 to 53.8) |
| Week 24 | -25 (-53.9 to 3.5) | -8.2 (-40.2 to 23.9) | -35 (-111 to 40.7) | -26 (-63.2 to 12.0) |
| Week 52 | 11.5 (-40.5 to 63.5) | -1.6 (-32.6 to 29.4) | 9.3 (-56.4 to 75.1) | 11.6 (-26.6 to 49.7) |
HOMA insulin resistance, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
| Insulin Resistance Index | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | 0.3 (-0.6 to 1.2) | 0.1 (-0.9 to 1.0) | -1.1 (-5.2 to 3.1) | -0.3 (-2.0 to 1.3) |
| Week 12 | -0.1 (-1.5 to 1.4) | 0.6 (-0.7 to 1.8) | -0.1 (-2.5 to 2.3) | -0.4 (-2.0 to 1.3) |
| Week 24 | -0.3 (-1.1 to 0.6) | 0.6 (-1.3 to 2.5) | -1.1 (-5.0 to 2.8) | -0.7 (-2.2 to 0.8) |
| Week 52 | -0.2 (-1.2 to 0.9) | 0.6 (-0.3 to 1.4) | -0.2 (-2.8 to 2.4) | 0.7 (-1.9 to 3.4) |
Hemoglobin A1c (glycated hemoglobin), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
| millimole per mole of Haemoglobin | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | 0.2 (-0.5 to 0.8) | -0.4 (-1.0 to 0.3) | -0.7 (-2.3 to 1.0) | -0.4 (-1.2 to 0.4) |
| Week 12 | 0.4 (-0.7 to 1.5) | -0.4 (-2.2 to 1.4) | -1.2 (-3.8 to 1.3) | 0.1 (-0.8 to 1.0) |
| Week 24 | -0.4 (-1.7 to 1.0) | -1.2 (-2.9 to 0.5) | -0.1 (-2.4 to 2.1) | -1.2 (-2.9 to 0.6) |
| Week 52 | -1.1 (-2.3 to 0.1) | -2.8 (-6.1 to 0.4) | -1.9 (-4.3 to 0.6) | -2.1 (-3.0 to 1.2) |
Sex hormone-binding globulin (SHBG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.
| nanomole per Liter (nmol/L) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | 0.1 (-1.8 to 2.1) | 3.7 (-3.0 to 10.4) | 4.7 (-4.2 to 13.5) | -0.3 (-4.0 to 3.5) |
| Week 12 | -0.1 (-3.4 to 3.2) | 1.1 (-1.8 to 4.1) | 3.7 (-1.6 to 9.1) | 4.1 (-0.2 to 8.4) |
| Week 24 | -1.5 (-5.1 to 2.2) | 3.2 (-0.9 to 7.2) | 1.7 (-2.9 to 6.3) | 2.6 (-1.5 to 6.7) |
| Week 52 | -3.1 (-10.8 to 4.6) | 5.9 (-1.3 to 13.0) | -2.6 (-14.9 to 9.6) | 3.2 (-4.3 to 10.8) |
Triglycerides, Total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB), soluble biomarkers of impaired lipid metabolism were determined in fasting blood samples to evaluate the effect of secukinumab on impaired lipid metabolism.
| mg/dL | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Triglycerides Week 4 | -1.8 (-15.5 to 12.0) | 6.5 (-5.9 to 18.9) | 12.7 (-12.2 to 37.7) | 27.5 (-6.6 to 61.6) |
| Triglycerides Week 12 | -9.3 (-20.8 to 2.3) | 4.0 (-9.3 to 17.3) | 5.9 (-32.4 to 44.2) | 2.7 (-18.3 to 23.8) |
| Triglycerides Week 24 | 4.6 (-16.6 to 25.8) | 3.9 (-9.1 to 16.9) | 32.8 (-19.7 to 85.2) | 17.1 (-2.3 to 36.5) |
| Triglycerides Week 52 | 64.6 (-44.0 to 173.2) | 2.6 (-11.7 to 16.9) | -6.0 (-54.3 to 42.3) | 11.9 (-8.6 to 32.3) |
| Total cholesterol Week 4 | 0.4 (-6.4 to 7.1) | 7.1 (1.1 to 13.2) | 4.8 (-3.2 to 12.8) | -2.7 (-10.0 to 4.7) |
| Total cholesterol Week 12 | 3.1 (-3.1 to 9.4) | 3.6 (-4.1 to 11.2) | 10.0 (2.8 to 17.1) | -4.2 (-11.2 to 2.8) |
| Total cholesterol Week 24 | 0.9 (-5.2 to 7.1) | 0.6 (-4.9 to 6.1) | 7.2 (-1.5 to 16.0) | -3.2 (-12.0 to 5.5) |
| Total cholesterol Week 52 | 7.8 (0.0 to 15.6) | 2.3 (-5.2 to 9.9) | 8.9 (2.1 to 15.7) | 2.9 (-5.9 to 11.7) |
| LDL Week 4 | 1.1 (-4.6 to 6.8) | 6.8 (0.8 to 12.8) | 5.2 (-2.0 to 12.4) | -5.6 (-12.1 to 0.8) |
| LDL Week 12 | 2.9 (-2.2 to 7.9) | 2.7 (-4.8 to 10.1) | 9.5 (3.4 to 15.5) | -5.6 (-12.7 to 1.5) |
| LDL Week 24 | -2.7 (-8.1 to 2.7) | -1.3 (-6.9 to 4.4) | 1.1 (-7.4 to 9.5) | -11 (-18.9 to -2.4) |
| LDL Week 52 | 1.7 (-6.5 to 9.9) | -0.9 (-8.4 to 6.5) | 8.2 (1.3 to 15.0) | 1.1 (-8.4 to 10.5) |
| HDL Week 4 | -0.6 (-2.6 to 1.3) | 0.4 (-1.5 to 2.2) | 0.3 (-2.3 to 2.9) | -1.3 (-4.6 to 2.0) |
| HDL Week 12 | -0.4 (-2.4 to 1.6) | 0.2 (-1.8 to 2.2) | 1.0 (-1.2 to 3.3) | -0.5 (-4.9 to 3.8) |
| HDL Week 24 | 1.2 (-1.5 to 3.9) | 0.3 (-2.3 to 2.8) | -1.1 (-3.4 to 1.3) | 0.5 (-4.1 to 5.1) |
| HDL Week 52 | 0.1 (-2.1 to 2.4) | 1.8 (-0.5 to 4.2) | -0.3 (-2.9 to 2.4) | -1.4 (-4.6 to 1.8) |
| ApoA-1 Week 4 | 0.3 (-5.1 to 5.7) | 0.9 (-4.0 to 5.7) | 7.7 (-0.6 to 15.9) | -5.5 (-12.0 to 1.0) |
| ApoA-1 Week 12 | 4.0 (-2.0 to 10.1) | 2.4 (-1.9 to 6.8) | 7.1 (1.2 to 12.9) | -3.3 (-12.1 to 5.5) |
| ApoA-1 Week 24 | 5.5 (-0.9 to 12.0) | 2.8 (-3.0 to 8.6) | 3.0 (-3.3 to 9.3) | -3.1 (-11.3 to 5.1) |
| ApoA-1 Week 52 | -4.5 (-10.0 to 0.9) | -6.0 (-11.6 to -0.3) | -5.5 (-14.9 to 3.9) | -13 (-22.3 to -3.1) |
| ApoB Week 4 | 1.5 (-2.7 to 5.6) | 3.6 (0.5 to 6.6) | 2.7 (-1.1 to 6.5) | -2.5 (-7.7 to 2.8) |
| ApoB Week 12 | 4.0 (0.6 to 7.4) | 3.4 (-0.5 to 7.3) | 7.4 (3.9 to 11.0) | -1.0 (-7.0 to 4.9) |
| ApoB Week 24 | 1.0 (-2.8 to 4.8) | 2.0 (-1.3 to 5.3) | 5.6 (1.4 to 9.9) | -4.2 (-10.7 to 2.3) |
| ApoB Week 52 | 3.7 (-2.2 to 9.6) | 2.3 (-1.8 to 6.4) | 6.7 (3.0 to 10.5) | -0.2 (-5.4 to 5.0) |
Adiponectin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
| ug/mL | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | -0.5 (-1.0 to -0.1) | 0.2 (-0.4 to 0.8) | -0.1 (-0.8 to 0.5) | -0.6 (-1.2 to -0.0) |
| Week 12 | -0.5 (-1.1 to -0.0) | -0.2 (-0.7 to 0.3) | 0.5 (0.1 to 0.9) | 0.3 (-0.7 to 1.3) |
| Week 24 | 0.3 (-0.3 to 0.9) | 0.1 (-0.5 to 0.7) | 0.7 (-0.3 to 1.8) | -0.6 (-1.6 to 0.3) |
| Week 52 | -1.1 (-1.6 to -0.6) | -0.9 (-1.5 to -0.3) | -0.4 (-1.0 to 0.2) | -1.1 (-2.0 to -0.3) |
Leptin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.
| ng/mL (nanogram per milliliter) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab |
|---|---|---|---|---|
| Week 4 | -0.6 (-1.8 to 0.7) | 1.0 (-0.1 to 2.2) | -0.2 (-1.6 to 1.2) | 0.3 (-1.2 to 1.9) |
| Week 12 | 0.2 (-0.7 to 1.1) | 0.1 (-0.9 to 1.2) | 0.7 (-1.0 to 2.4) | -0.3 (-1.7 to 1.2) |
| Week 24 | 0.2 (-0.7 to 1.2) | 1.0 (-0.5 to 2.4) | -0.3 (-2.8 to 2.3) | -1.4 (-4.9 to 2.1) |
| Week 52 | 0.2 (-1.0 to 1.3) | -0.5 (-1.6 to 0.7) | -0.4 (-3.8 to 3.0) | -2.9 (-5.7 to 0.0) |
Collected over From signing of Informed Consent up to 30 days post last drug treatment.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab (300 mg) up to Week 12 | — | 1/48 (2.1%) | 29/48 (60.4%) |
| Secukinumab (150 mg) up to Week 12 | — | 0/54 (0%) | 36/54 (66.7%) |
| Placebo up to Week 12 | — | 2/49 (4.1%) | 35/49 (71.4%) |
| Secukinumab (300 mg) After Week 12 | — | 6/48 (12.5%) | 36/48 (75%) |
| Secukinumab (150 mg) After Week 12 | — | 6/54 (11.1%) | 43/54 (79.6%) |
| Placebo Followed by Secukinumab (300 mg) After Week 12 | — | 0/26 (0%) | 21/26 (80.8%) |
| Placebo Followed by Secukinumab (150 mg) After Week 12 | — | 1/23 (4.3%) | 19/23 (82.6%) |
| Event | Secukinumab (300 mg) up to Week 12 | Secukinumab (150 mg) up to Week 12 | Placebo up to Week 12 | Secukinumab (300 mg) After Week 12 | Secukinumab (150 mg) After Week 12 | Placebo Followed by Secukinumab (300 mg) After Week 12 | Placebo Followed by Secukinumab (150 mg) After Week 12 |
|---|---|---|---|---|---|---|---|
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 0/48 | 0/54 | 0/49 | 0/48 | 0/54 | 0/26 | 1/23 |
| VESTIBULAR DISORDEREar and labyrinth disorders | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| DUODENAL ULCERGastrointestinal disorders | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| GASTRIC ULCERGastrointestinal disorders | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| GASTRITIS EROSIVEGastrointestinal disorders | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| ANAL ABSCESSInfections and infestations | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| ERYSIPELASInfections and infestations | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| HELICOBACTER INFECTIONInfections and infestations | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| PNEUMONIA BACTERIALInfections and infestations | 1/48 | 0/54 | 0/49 | 0/48 | 0/54 | 0/26 | 0/23 |
| JOINT DISLOCATIONInjury, poisoning and procedural complications | 0/48 | 0/54 | 0/49 | 1/48 | 0/54 | 0/26 | 0/23 |
| Event | Secukinumab (300 mg) up to Week 12 | Secukinumab (150 mg) up to Week 12 | Placebo up to Week 12 | Secukinumab (300 mg) After Week 12 | Secukinumab (150 mg) After Week 12 | Placebo Followed by Secukinumab (300 mg) After Week 12 | Placebo Followed by Secukinumab (150 mg) After Week 12 |
|---|---|---|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 10/48 | 14/54 | 18/49 | 21/48 | 25/54 | 10/26 | 10/23 |
| BACK PAINMusculoskeletal and connective tissue disorders | 2/48 | 2/54 | 1/49 | 4/48 | 4/54 | 5/26 | 1/23 |
| RHINITISInfections and infestations | 1/48 | 0/54 | 2/49 | 2/48 | 3/54 | 1/26 | 4/23 |
| HEADACHENervous system disorders | 4/48 | 6/54 | 2/49 | 7/48 | 7/54 | 2/26 | 0/23 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 1/48 | 2/54 | 5/49 | 5/48 | 3/54 | 0/26 | 3/23 |
| DIARRHOEAGastrointestinal disorders | 2/48 | 2/54 | 1/49 | 0/48 | 3/54 | 3/26 | 1/23 |
| CONJUNCTIVITISInfections and infestations | 0/48 | 0/54 | 0/49 | 0/48 | 1/54 | 2/26 | 0/23 |
| HAEMATURIARenal and urinary disorders | 2/48 | 2/54 | 0/49 | 1/48 | 0/54 | 2/26 | 0/23 |
| RHINITIS ALLERGICRespiratory, thoracic and mediastinal disorders | 0/48 | 1/54 | 0/49 | 0/48 | 0/54 | 2/26 | 0/23 |
| COUGHRespiratory, thoracic and mediastinal disorders | 2/48 | 0/54 | 3/49 | 2/48 | 4/54 | 1/26 | 0/23 |
| Age, Categorical(Participants) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 46 | 46 | 26 | 22 | 140 |
| >=65 years | 2 | 8 | 0 | 1 | 11 |
| Age, Continuous(years) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab | Total |
|---|---|---|---|---|---|
| Mean | 44.2 ± 12.9 | 46.0 ± 14.4 | 43.7 ± 11.4 | 46.8 ± 13.1 | 45.2 ± 13.2 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab | Total |
|---|---|---|---|---|---|
| Female | 11 | 23 | 8 | 7 | 49 |
| Male | 37 | 31 | 18 | 16 | 102 |
| Region of Enrollment(participants) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo Followed by 300 mg Secukinumab | Placebo Followed by 150 mg Secukinumab | Total |
|---|---|---|---|---|---|
| Germany | 48 | 54 | 26 | 23 | 151 |
The record gives a start of Apr 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab